Announced Tue, 13 Oct, 2026 · 20:22 IST

Reg 74(5) certificate submitted for quarter ended September 2026

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹239.95

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+0.6% vs market

Pharmaceuticals peers, median of 172sector-0.0%+1.4% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.7+0.6-0.0+1.4

Next day

-3.7-1.0-2.7-0.8-2.9

+5.9-0.3+6.2-0.6+6.5

+13.3-1.9+15.2-1.9+15.2

+14.1-4.5+18.6-3.5+17.7

+21.6-5.5+27.0-4.4+26.0

+12.6-7.3+19.8-4.4+17.0

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Samrat Pharmachem has submitted to BSE the Regulation 74(5) certificate from its Registrar MUFG Intime India for the quarter ended September 30, 2026. The certificate confirms that securities received for dematerialization during the quarter were processed, listed on stock exchanges, and registered in the depository within required timelines. This is a routine quarterly compliance filing under SEBI depository rules.

Likely market impact

Routine regulatory compliance filing. No impact on shareholders or stock price.